XORTX Therapeutics Inc.(XRTX)Earnings, Financials & Key Ratios
XRTX•NASDAQ
$2.76
$768630 mkt cap·Price updated May 6, 2026
AboutXORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$4M+19.9%
- Net Income-$4M+18.2%
- EPS (Diluted)-19.50+50.6%
- ROE-96.96%-0.8%
- ROIC-225.96%+33.2%
- Debt/Equity0.02+53.9%
XRTX Key Insights
XORTX Therapeutics Inc. (XRTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 23.6% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 64.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
XRTX Price & Volume
XORTX Therapeutics Inc. (XRTX) stock price & volume — 10-year historical chart
Loading chart...
XRTX Growth Metrics
XORTX Therapeutics Inc. (XRTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.02%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.99%
Return on Capital
10 Years-206.71%
5 Years-82.77%
3 Years-97.31%
Last Year-118.85%
XRTX Peer Comparison
XORTX Therapeutics Inc. (XRTX) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 CPRX | 3.74B | 30.52 | 18.17 | 19.78% | 36.39% | 22.46% | 0.00 | |
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare XRTX vs Peers
XORTX Therapeutics Inc. (XRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XRTX Income Statement
XORTX Therapeutics Inc. (XRTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 19.32K | 19.9K | 20.44K | 17.88K | 75.27K | 141.96K | 160.66K | 156.66K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -19.32K▲ 0% | -19.9K▼ 3.0% | -20.44K▼ 2.7% | -17.88K▲ 12.5% | -75.27K▼ 320.9% | -141.96K▼ 88.6% | -160.66K▼ 13.2% | -156.66K▲ 2.5% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | -3.02% | -2.71% | 12.51% | -320.91% | -88.6% | -13.17% | 2.49% |
| Operating Expenses | 464.07K | 1.16M | 546.07K | 1.3M | 2.9M | 9.86M | 4.81M | 5.48M | 4.39M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 380.92K | 795.65K | 506.17K | 624.49K | 2.05M | 3.28M | 2.39M | 5.23M | 3.59M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 66.37K | 342.25K | 39.9K | 277.45K | 853.12K | 6.49M | 2.41M | 251.84K | 803.35K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -427.11K▲ 0% | -1.07M▼ 150.4% | -565.97K▲ 47.1% | -1.08M▼ 91.2% | -2.9M▼ 168.2% | -12.43M▼ 328.3% | -4.81M▲ 61.4% | -5.64M▼ 17.4% | -4.55M▲ 19.4% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -9.71% | -150.37% | 47.07% | -91.22% | -168.23% | -328.32% | 61.35% | -17.42% | 19.36% |
| EBITDA | -410.33K | -1.05M | -546.07K | -1.06M | -2.88M | -12.36M | -4.62M | -5.48M | -4.39M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -9.92% | -155.9% | 48% | -94.45% | -171.71% | -328.37% | 62.64% | -18.73% | 19.86% |
| D&A (Non-Cash Add-back) | 16.78K | 19.32K | 19.9K | 20.44K | 17.88K | 75.27K | 188.54K | 160.66K | 156.66K |
| EBIT | -443.88K | -1.09M | -592.37K | -1.27M | -2.92M | -9.49M | -6.57M | -4.54M | -4.55M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 167.01K | 58.5K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 101.37K | 342.2K | 167.01K | 58.5K |
| Interest Expense | 15.46K | 22.3K | 37.21K | 13.51K | 4.39K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -47.09K | -2.71M | -63.61K | -202.36K | 1.25M | 2.95M | 1.95M | 1.1M | 837.97K |
| Pretax Income | -474.2K▲ 0% | -3.78M▼ 696.3% | -629.58K▲ 83.3% | -1.28M▼ 104.0% | -1.65M▼ 28.6% | -9.49M▼ 474.1% | -2.86M▲ 69.9% | -4.54M▼ 58.7% | -3.71M▲ 18.2% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 4.39K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.27% | 0% | 0% | 0% | 0% |
| Net Income | -474.2K▲ 0% | -3.78M▼ 696.3% | -629.58K▲ 83.3% | -1.28M▼ 104.0% | -1.65M▼ 28.6% | -6.99M▼ 323.0% | -2.86M▲ 59.1% | -4.54M▼ 58.7% | -3.71M▲ 18.2% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -14.31% | -696.27% | 83.33% | -104.04% | -28.62% | -322.98% | 59.09% | -58.75% | 18.23% |
| Net Income (Continuing) | -474.2K | -3.78M | -629.58K | -1.28M | -1.65M | -9.49M | -2.86M | -4.54M | -3.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -55.75▲ 0% | -150.75▼ 170.4% | -25.25▲ 83.3% | -43.25▼ 71.3% | -30.00▲ 30.6% | -118.00▼ 293.3% | -36.00▲ 69.5% | -39.50▼ 9.7% | -19.50▲ 50.6% |
| EPS Growth % | 3.88% | -170.4% | 83.25% | -71.29% | 30.64% | -293.33% | 69.49% | -9.72% | 50.63% |
| EPS (Basic) | -55.75 | -150.75 | -25.25 | -43.25 | -30.00 | -118.00 | -36.00 | -39.50 | -19.50 |
| Diluted Shares Outstanding | 8.51K | 25.04K | 25.04K | 29.62K | 43.77K | 59.2K | 79.27K | 115.14K | 189.38K |
| Basic Shares Outstanding | 8.49K | 25.04K | 25.04K | 29.62K | 43.77K | 59.2K | 79.27K | 115.14K | 189.38K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
XRTX Balance Sheet
XORTX Therapeutics Inc. (XRTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 63.55K | 979.65K | 624.1K | 2.06M | 15.91M | 10.9M | 4.07M | 3.85M | 1.33M |
| Cash & Short-Term Investments | 61.94K | 260.02K | 58.61K | 171.27K | 14.79M | 10.43M | 3.45M | 3.56M | 1.19M |
| Cash Only | 49.26K | 190.91K | 58.61K | 171.27K | 14.87M | 10.43M | 3.45M | 3.56M | 1.19M |
| Short-Term Investments | 12.68K | 69.11K | 0 | 0 | -84.8K | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 30.26K | 15.47K | 11.25K | 40.65K | 81.75K | 60.71K | 25.36K | 109.89K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 168.81K | -11.25K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 3.1K | - | - | - | - | - | - |
| Other Current Assets | 1.61K | 719.63K | 64.95K | 1.62M | 0 | 0 | 323.44K | 0 | 0 |
| Total Non-Current Assets | 427.06K | 285.59K | 272.73K | 234.32K | 1.47M | 1.48M | 1.4M | 2.04M | 2.35M |
| Property, Plant & Equipment | 891 | 731 | 341 | 0 | 0 | 92.68K | 23.93K | 49.94K | 50.81K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 403 | 0 | 0 | 0 |
| Intangible Assets | 258.71K | 284.86K | 272.39K | 234.32K | 202.13K | 199.43K | 175.25K | 263.35K | 254.09K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.73M | 1.64M |
| Other Non-Current Assets | 167.45K | 0 | 0 | 0 | 1.27M | 1.19M | 1.2M | 0 | 402.73K |
| Total Assets | 490.6K▲ 0% | 1.27M▲ 157.9% | 1.09M▼ 14.0% | 2.29M▲ 110.5% | 17.38M▲ 658.9% | 12.37M▼ 28.8% | 5.47M▼ 55.8% | 5.89M▲ 7.7% | 3.68M▼ 37.5% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 73.69% | 157.9% | -14.01% | 110.52% | 658.88% | -28.81% | -55.81% | 7.7% | -37.53% |
| Total Current Liabilities | 1.11M | 900.45K | 1.3M | 1.03M | 552.95K | 1.51M | 294.94K | 1.09M | 821.18K |
| Accounts Payable | 331.36K | 304.5K | 607.39K | 305.83K | 323.96K | 1.29M | 195.81K | 84.02K | 0 |
| Days Payables Outstanding | - | 5.75K | 11.14K | 5.46K | 6.61K | 6.27K | 503.47 | 190.88 | - |
| Short-Term Debt | 188.23K | 0 | 50.81K | 0 | 0 | 0 | 0 | 55.78K | 51.11K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 142.56K | 102.31K | 97.41K | 0 | 0 | 0 | 0 | 950.34K | 770.07K |
| Current Ratio | 0.06x | 1.09x | 0.48x | 1.99x | 28.78x | 7.21x | 13.80x | 3.53x | 1.61x |
| Quick Ratio | 0.06x | 1.09x | 0.35x | 2.00x | 28.78x | 7.21x | 13.80x | 3.53x | 1.61x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35.77K | 43.26K | 0 | 0 | 3.63M | 3.87M | 531K | 0 | 0 |
| Long-Term Debt | 28.44K | 43.26K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 11.51K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.33K | 0 | 0 | 0 | 3.63M | 3.85M | 531K | 0 | 0 |
| Total Liabilities | 1.15M | 943.7K | 1.3M | 1.03M | 4.18M | 5.38M | 825.94K | 1.09M | 821.18K |
| Total Debt | 216.67K | 43.26K | 50.81K | 0 | 0 | 77.6K | 11.51K | 55.78K | 51.11K |
| Net Debt | 167.41K | -216.76K | -7.8K | -171.27K | -14.87M | -10.36M | -3.44M | -3.5M | -1.13M |
| Debt / Equity | - | 0.13x | - | - | - | 0.01x | 0.00x | 0.01x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -28.71x | -48.82x | -15.92x | -94.07x | -665.28x | - | - | - | - |
| Total Equity | -654.63K▲ 0% | 321.54K▲ 149.1% | -211.72K▼ 165.8% | 1.26M▲ 693.3% | 13.2M▲ 951.0% | 7M▼ 47.0% | 4.64M▼ 33.7% | 4.8M▲ 3.4% | 2.86M▼ 40.5% |
| Equity Growth % | -106.47% | 149.12% | -165.85% | 693.35% | 950.96% | -47% | -33.66% | 3.37% | -40.46% |
| Book Value per Share | -76.97 | 12.84 | -8.46 | 42.41 | 301.67 | 118.20 | 58.56 | 41.68 | 15.09 |
| Total Shareholders' Equity | -654.63K | 321.54K | -211.72K | 1.26M | 13.2M | 7M | 4.64M | 4.8M | 2.86M |
| Common Stock | 1.39M | 5.86M | 5.86M | 8.26M | 16.09M | 16.52M | 17.06M | 26.6M | 27.67M |
| Retained Earnings | -1.87M | -6.13M | -6.76M | -8.04M | -7.98M | -15.7M | -23.54M | -30.44M | -32.66M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 296.54K | 586.69K | 683K | 1.04M | 0 | 8.04M | 5.4M | 8.65M | 7.85M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XRTX Cash Flow Statement
XORTX Therapeutics Inc. (XRTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 72.5K | -1.56M | -249.58K | -728.4K | -4.8M | -8.96M | -6.58M | -5.04M | -3.87M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 167.27% | -2245.2% | 83.95% | -191.85% | -559.12% | -86.7% | 26.56% | 23.45% | 23.23% |
| Net Income | -377.1K | -3.78M | -481.96K | -1.01M | -1.58M | -7.72M | -2.16M | -4.54M | -3.71M |
| Depreciation & Amortization | 13.34K | 14.18K | 15.23K | 20.44K | 14.27K | 58.15K | 105.18K | 160.66K | 156.66K |
| Stock-Based Compensation | 92.67K | 275.09K | 26.32K | 293.44K | 576.01K | 487.94K | 120.98K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 34.06K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 106.86K | 2.58M | -211.31K | -397.09K | -2.73M | -2.58M | -3.62M | -821.11K | -783.53K |
| Working Capital Changes | 236.72K | -651.93K | 368.08K | 362.21K | -1.08M | 787.32K | -1.03M | 160K | 469.79K |
| Change in Receivables | 0 | -20.06K | 14.79K | 0 | -29.17K | -43.61K | 21 | 59.01K | -87.38K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -12.48K | -154.81K | -7.04K | -14.35K | -31.81K | -45.7K | -46.36K | -53.32K | -412.13K |
| Capital Expenditures | -1.17K | 0 | -5.39K | -11.25K | -31.22K | -44.22K | -6 | -53.32K | -77.16K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | -167 | -280.95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -11.15K | 126.15K | -1.65K | -3.1K | -585 | -1.48K | -46.36K | 0 | -334.97K |
| Cash from Financing | 106.32K | 1.4M | 42.27K | 670.82K | 19.37M | 4.71M | -487.3K | 3.81M | 1.99M |
| Debt Issued (Net) | 79.52K | 0 | 0 | 0 | 0 | -20.41K | -66.09K | -69.72K | 0 |
| Equity Issued (Net) | 0 | 1.44M | 70K | 705.79K | 18.07M | 5M | 0 | 3.9M | 2.12M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 26.8K | -36.07K | -27.73K | -34.97K | 1.3M | -269.49K | -421.21K | -25.8K | -125.16K |
| Net Change in Cash | 35.92K▲ 0% | 198.08K▲ 451.4% | -201.41K▼ 201.7% | 112.66K▲ 155.9% | 14.74M▲ 12979.8% | -4.44M▼ 130.1% | -6.99M▼ 57.5% | -974.02K▲ 86.1% | -2.37M▼ 143.6% |
| Free Cash Flow | 62.58K▲ 0% | -1.6M▼ 2651.2% | -196.45K▲ 87.7% | -742.75K▼ 278.1% | -4.83M▼ 550.7% | -9.01M▼ 86.4% | -6.63M▲ 26.4% | -5.04M▲ 24.0% | -3.87M▲ 23.2% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 147.28% | -2651.19% | 87.69% | -278.09% | -550.67% | -86.42% | 26.41% | 23.98% | 23.23% |
| FCF per Share | 7.36 | -63.77 | -7.85 | -25.08 | -110.43 | -152.20 | -83.63 | -43.77 | -20.43 |
| FCF Conversion (FCF/Net Income) | -0.15x | 0.41x | 0.40x | 0.57x | 2.91x | 1.28x | 2.30x | 1.11x | 1.04x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XRTX Key Ratios
XORTX Therapeutics Inc. (XRTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -1174.33% | -1146.59% | -245.97% | -22.86% | -69.2% | -49.13% | -96.16% | -96.96% |
| Return on Invested Capital (ROIC) | - | - | - | - | -187.57% | - | - | - | -338.16% | -225.96% |
| Debt / Equity | - | - | 0.13x | - | - | - | 0.01x | 0.00x | 0.01x | 0.02x |
| Interest Coverage | -47.00x | -28.71x | -48.82x | -15.92x | -94.07x | -665.28x | - | - | - | - |
| FCF Conversion | 0.26x | -0.15x | 0.41x | 0.40x | 0.57x | 2.91x | 1.28x | 2.30x | 1.11x | 1.04x |
XRTX Frequently Asked Questions
XORTX Therapeutics Inc. (XRTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
XORTX Therapeutics Inc. (XRTX) grew revenue by 0.0% over the past year. Growth has been modest.
XORTX Therapeutics Inc. (XRTX) reported a net loss of $2.9M for fiscal year 2025.
Dividend & Returns
XORTX Therapeutics Inc. (XRTX) has a return on equity (ROE) of -97.0%. Negative ROE indicates the company is unprofitable.
XORTX Therapeutics Inc. (XRTX) had negative free cash flow of $3.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More XRTX
XORTX Therapeutics Inc. (XRTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates